No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

5/6

Chiesi

Farmaceutici

Gossamer Bio

Small molecule

(inhalational route,

seralutinib)

CSF1R, c-KIT, PDGF subtype A and B

Pulmonary arterial

hypertension (PAH)

Phase III

486

2

5/9

Novo Nordisk

Metaphore

Biotechnologies

Next-Generation Therapeutics

based on MIMIC platform

Glucagon like peptide 1 receptor
(GLP1R)

Obesity

Discovery

600

3

5/13

Takeda

Pharmaceutical

AC Immune SA

Liposomal anti-abeta vaccine

(SC route, ACI024060)

Amyloid precursor protein

Alzheimer’s disease,

Down syndrome

Phase II

2,200

4

5/13

MindBio

Therapeutics

Enveric Biosciences

Small molecule
(EB-002)

5-hydroxytryptamine receptor 2A

(5 HT2A)

Cancer related

distress (CRD),

anxiety disorders

Preclinical

66.5

5

5/22

AstraZeneca

Nona Biosciences

Monoclonal antibody
(unclarified)

n/d

Cancer

Preclinical

604

6

5/23

PDC FZ LLC

Roquefort

Therapeutics

Monoclonal antibody

(ROQA-1, ROQA-2)

Midkine

Metastatic cancer

(breast, liver, lung)

osteosarcoma

Preclinical

12.5

7

5/23

Takeda

Pharmaceutical

Degron Therapeutics

Small molecule

(Novel Molecular Glue Degraders)

molecular glue-based

targeted protein degradation

Inflammation,

Cancer,

Unspecified

Neurologic Disorders

Preclinical

1,200

8

5/26

BioNTech

Suzhou Medilink

Therapeutics

Monoclonal antibody

conjugated

(i.v. route, YL-202)

human anti-HER3 antibody &

a novel topoisomerase I inhibitor

Solid cancer

Phase II

1,825

9

5/28

HanAll

Biopharma

Turn Biotechnologies

Epigenetic Reprogramming

of Aging (ERA) technology &

eTurna delivery platform

-

ophthalmic

and otic disease

-

300

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

5/2

Novartis AG

Mariana

Oncology

(MC-339) Type : Small molecule, engineered to carry an actinium payload

Indication : Small-cell lung cancer

Stage : Preclinical

1,750

2

5/16

Johnson & Johnson

Proteologix Inc

(PC-128) Type : Monoclonal antibody

Target : IL13, TSLP

Indication : Asthma, Atopic Dermatitis

Stage : Preclinical

(PC-130) Type : Monoclonal antibody

Target : IL13, IL22

Indication : Atopic Dermatitis

Stage : Preclinical

850

3

5/22

Biogen

Human Immunology Biosciences

(felzartamab) Type : Monoclonal antibody

Target : Cyclic ADP Ribose Hydrolase 1

Indication : IgA Nephropathy (Berger's Disease), Antibody-Mediated Rejection, NSCLC,
Lupus Nephritis, Systemic Lupus Erythematosus, Multiple Myeloma

Stage : Pre-registration

1,800

4

5/22

AstraZeneca Plc

SixPeaks Bio AG

(Dual-specific antibody) Type : Bispecific antibody

Target : Activin Receptor Type 2A, Activin Receptor Type 2B

Indication : Obesity

Stage : Preclinical

80

5

5/28

Johnson & Johnson

Yellow Jersey Therapeutics

(NM-26) Type : Bispecific antibody

Target : IL31, IL4Ra

Indication : Atopic Dermatitis, Chronic Inflammation

Stage : 임상 1상

1,250

6

5/28

Asahi Kasei Corp

Calliditas Therapeutics AB

(budesonide DR) Type : Small molecule

Target : Glucocorticoid Receptor

Indication : IgA Nephropathy (Berger's Disease), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Autoimmune Hepatitis

Stage : IgA Nephropathy (Berger’s disease) - Marketed

1,049.8

7

5/28

Royalty Pharma

Agios Pharmaceuticals

(vorasidenib citrate) Type : Small molecule

Target : NADP Cytoplasmic/mitochondrial

Indication : hematological malignancies, solid tumors

Stage : Pre-registration

905

8

5/29

Merck & Co

Eyebiotech

(EYE-103) Type : Monoclonal antibody, Target : Frizzled4, LRP5

Indication : Diabetic Macular Edema, Diabetic Retinopathy, Retinopathy Of Prematurity,
Wet (Neovascular / Exudative) Macular Degeneration

Stage : 임상 2상

3,000